

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION**

Applicant(s): **BANDI PARTHASARADHI REDDY**

Serial No: 10/511,735

Group Art Unit: 1625

Filed: 10-18-2004

Examiner: CHANG, CELIA C

Att. Docket No.: H1089/20022

Confirmation No.: 2558

For: **NOVEL CRYSTALLINE FORMS OF DONEPEZIL HYDROCHLORIDE**

**IDS CERTIFICATION STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the concurrently filed Form PTO/SB/08a. Unless otherwise indicated herein, one copy of each reference is submitted herewith. No copies of U.S. patents or U.S. patent application publications are submitted herewith. 37 CFR § 1.98(a)(2)(ii). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed after the period specified in 37 CFR § 1.97(b), but before the mailing date of any of a final action under 37 CFR § 1.113, a Notice of Allowance under 37 CFR § 1.311 or an action that otherwise closes prosecution in the application. Authorization to charge the additional fee under 37 CFR §1.17(p) is granted in the concurrently filed Fee Transmittal Form.


Application No. 10/511,735  
IDS Certification Statement dated May 7, 2008

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

May 7, 2008

Please charge or credit our Account  
No. 03-0075 as necessary to effect  
entry and/or ensure consideration of  
this submission.

By   
Joseph F. Murphy  
Registration No. 58,313  
Customer No. 03000  
(215) 567-2010  
Attorneys for Applicant(s)